These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
391 related articles for article (PubMed ID: 30275007)
1. KDM6B overexpression activates innate immune signaling and impairs hematopoiesis in mice. Wei Y; Zheng H; Bao N; Jiang S; Bueso-Ramos CE; Khoury J; Class C; Lu Y; Lin K; Yang H; Ganan-Gomez I; Starczynowski DT; Do KA; Colla S; Garcia-Manero G Blood Adv; 2018 Oct; 2(19):2491-2504. PubMed ID: 30275007 [TBL] [Abstract][Full Text] [Related]
2. Cooperation between KDM6B overexpression and TET2 deficiency in the pathogenesis of chronic myelomonocytic leukemia. Wei Y; Kanagal-Shamanna R; Zheng H; Bao N; Lockyer PP; Class CA; Darbaniyan F; Lu Y; Lin K; Yang H; Montalban-Bravo G; Ganan-Gomez I; Soltysiak KA; Do KA; Colla S; Garcia-Manero G Leukemia; 2022 Aug; 36(8):2097-2107. PubMed ID: 35697791 [TBL] [Abstract][Full Text] [Related]
3. Global H3K4me3 genome mapping reveals alterations of innate immunity signaling and overexpression of JMJD3 in human myelodysplastic syndrome CD34+ cells. Wei Y; Chen R; Dimicoli S; Bueso-Ramos C; Neuberg D; Pierce S; Wang H; Yang H; Jia Y; Zheng H; Fang Z; Nguyen M; Ganan-Gomez I; Ebert B; Levine R; Kantarjian H; Garcia-Manero G Leukemia; 2013 Nov; 27(11):2177-86. PubMed ID: 23538751 [TBL] [Abstract][Full Text] [Related]
4. Deconstructing innate immune signaling in myelodysplastic syndromes. Varney ME; Melgar K; Niederkorn M; Smith M; Barreyro L; Starczynowski DT Exp Hematol; 2015 Aug; 43(8):587-598. PubMed ID: 26143580 [TBL] [Abstract][Full Text] [Related]
5. Therapeutic potential of GSK-J4, a histone demethylase KDM6B/JMJD3 inhibitor, for acute myeloid leukemia. Li Y; Zhang M; Sheng M; Zhang P; Chen Z; Xing W; Bai J; Cheng T; Yang FC; Zhou Y J Cancer Res Clin Oncol; 2018 Jun; 144(6):1065-1077. PubMed ID: 29594337 [TBL] [Abstract][Full Text] [Related]
6. S100A9-induced overexpression of PD-1/PD-L1 contributes to ineffective hematopoiesis in myelodysplastic syndromes. Cheng P; Eksioglu EA; Chen X; Kandell W; Le Trinh T; Cen L; Qi J; Sallman DA; Zhang Y; Tu N; Adams WA; Zhang C; Liu J; Cleveland JL; List AF; Wei S Leukemia; 2019 Aug; 33(8):2034-2046. PubMed ID: 30737486 [TBL] [Abstract][Full Text] [Related]
7. Toll-like receptor alterations in myelodysplastic syndrome. Wei Y; Dimicoli S; Bueso-Ramos C; Chen R; Yang H; Neuberg D; Pierce S; Jia Y; Zheng H; Wang H; Wang X; Nguyen M; Wang SA; Ebert B; Bejar R; Levine R; Abdel-Wahab O; Kleppe M; Ganan-Gomez I; Kantarjian H; Garcia-Manero G Leukemia; 2013 Sep; 27(9):1832-40. PubMed ID: 23765228 [TBL] [Abstract][Full Text] [Related]
8. Caspase 8 deletion causes infection/inflammation-induced bone marrow failure and MDS-like disease in mice. Liu S; Joshi K; Zhang L; Li W; Mack R; Runde A; Hagen PA; Barton K; Breslin P; Ji HL; Kini AR; Wang Z; Zhang J Cell Death Dis; 2024 Apr; 15(4):278. PubMed ID: 38637559 [TBL] [Abstract][Full Text] [Related]
9. Leukemia cells impair normal hematopoiesis and induce functionally loss of hematopoietic stem cells through immune cells and inflammation. Cui P; Zhang Y; Cui M; Li Z; Ma G; Wang R; Wang N; Huang S; Gao J Leuk Res; 2018 Feb; 65():49-54. PubMed ID: 29306107 [TBL] [Abstract][Full Text] [Related]
10. Loss of Tifab, a del(5q) MDS gene, alters hematopoiesis through derepression of Toll-like receptor-TRAF6 signaling. Varney ME; Niederkorn M; Konno H; Matsumura T; Gohda J; Yoshida N; Akiyama T; Christie S; Fang J; Miller D; Jerez A; Karsan A; Maciejewski JP; Meetei RA; Inoue J; Starczynowski DT J Exp Med; 2015 Oct; 212(11):1967-85. PubMed ID: 26458771 [TBL] [Abstract][Full Text] [Related]
12. SWI/SNF subunit expression heterogeneity in human aplastic anemia stem/progenitors. Sinha S; Chatterjee SS; Biswas M; Nag A; Banerjee D; De R; Sengupta A Exp Hematol; 2018 Jun; 62():39-44.e2. PubMed ID: 29596882 [TBL] [Abstract][Full Text] [Related]
13. JMJD3 aids in reprogramming of bone marrow progenitor cells to hepatic phenotype through epigenetic activation of hepatic transcription factors. Kochat V; Equbal Z; Baligar P; Kumar V; Srivastava M; Mukhopadhyay A PLoS One; 2017; 12(3):e0173977. PubMed ID: 28328977 [TBL] [Abstract][Full Text] [Related]
14. Computing cell state discriminates the aberrant hematopoiesis and activated microenvironment in Myelodysplastic syndrome (MDS) through a single cell genomic study. Guo X; Jin W; Wen Y; Wang Z; Ren X; Liu Z; Fu R; Cai Z; Li L J Transl Med; 2024 Jul; 22(1):673. PubMed ID: 39033303 [TBL] [Abstract][Full Text] [Related]
15. Pharmacological targeting of KDM6A and KDM6B, as a novel therapeutic strategy for treating craniosynostosis in Saethre-Chotzen syndrome. Pribadi C; Camp E; Cakouros D; Anderson P; Glackin C; Gronthos S Stem Cell Res Ther; 2020 Dec; 11(1):529. PubMed ID: 33298158 [TBL] [Abstract][Full Text] [Related]
19. Alcohol-induced suppression of KDM6B dysregulates the mineralization potential in dental pulp stem cells. Hoang M; Kim JJ; Kim Y; Tong E; Trammell B; Liu Y; Shi S; Lee CR; Hong C; Wang CY; Kim Y Stem Cell Res; 2016 Jul; 17(1):111-21. PubMed ID: 27286573 [TBL] [Abstract][Full Text] [Related]
20. Dysregulated hematopoiesis caused by mammary cancer is associated with epigenetic changes and hox gene expression in hematopoietic cells. Sio A; Chehal MK; Tsai K; Fan X; Roberts ME; Nelson BH; Grembecka J; Cierpicki T; Krebs DL; Harder KW Cancer Res; 2013 Oct; 73(19):5892-904. PubMed ID: 23913828 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]